Risk–benefit analysis of adalimumab vers
✍
Edward V. Loftus Jr; Scott J. Johnson; Si-Tien Wang; Eric Wu; Parvez M. Mulani;
📂
Article
📅
2011
🏛
John Wiley and Sons
🌐
English
⚖ 474 KB
👁 1 views
Background: Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. Methods: A base-case analysis